Anamorelin Hydrochloride in the Treatment of Cancer Anorexia-Cachexia Syndrome
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Anamorelin hydrochloride is an orally active ghrelin receptor agonist in development by Helsinn, for the treatment of non-small-cell lung cancer (NSCLC) cachexia. In preclinical and clinical studies, the potent affinity of anamorelin for the ghrelin receptor is associated with significant appetite-enhancing activity and resultant improvements in body weight, lean body mass, and handgrip strength compared with placebo. The accompanying stimulatory effects on growth hormone and IGF-1 are not associated with tumor growth, and overall survival in patients with cancer is not compromised. Anamorelin is well tolerated with no dose-limiting toxicities identified to date. The findings of ongoing Phase III studies are needed to confirm the significant potential of anamorelin to treat NSCLC cachexia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Newman, A. B., Kupelian, V., Visser, M., Simonsick, E. M., Goodpaster, B. H., Kritchevsky, S. B., Tylavsky, F. A., Rubin, S. M., Harris, T. B., & on Behalf of the Health, A. A. B. C. S. I. (2006) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/61.1.72 · Cited by 1,692
Dobs, A. S., Boccia, R. V., Croot, C. C., Gabrail, N. Y., Dalton, J. T., Hancock, M. L., Johnston, M. A., & Steiner, M. S. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70055-x · Cited by 391
Dodson, S., Baracos, V. E., Jatoi, A., Evans, W. J., Cella, D., Dalton, J. T., & Steiner, M. S. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-061509-131248 · Cited by 319
Garcia, J. M., & Polvino, W. J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-5-594 · Cited by 129
Garcia, J. M., & Polvino, W. J. (2009) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2008.12.003 · Cited by 89
Cited by
Cancer cachexia: understanding the molecular basis
Argilés, J. M., Busquets, S., Stemmler, B., & López-Soriano, F. J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3829 · Cited by 1,517
Müller, T. D., Nogueiras, R., Andermann, M. L., Andrews, Z. B., Anker, S. D., Argente, J., Batterham, R. L., Benoit, S. C., Bowers, C. Y., Broglio, F., et al. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.03.005 · Cited by 1,034
Katakami, N., Uchino, J., Yokoyama, T., Naito, T., Kondo, M., Yamada, K., Kitajima, H., Yoshimori, K., Sato, K., Saito, H., et al. (2018) · Cancer · doi:10.1002/cncr.31128 · Cited by 239
“Anamorelin (ONO-7643) is an orally active, highaffinity, selective agonist of the ghrelin receptor.(14,15) Previous phase 1 and 2 trials have demonstrated the safety and efficacy of anamorelin treatment for increasing body weight, lean body mass (LBM), and food intake.”
BackgroundGarcia, J. M., Boccia, R. V., Graham, C. D., Yan, Y., Duus, E. M., Allen, S., & Friend, J. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71154-4 · Cited by 218
Skeletal muscle atrophy: Potential therapeutic agents and their mechanisms of action
Dutt, V., Gupta, S., Dabur, R., Injeti, E., & Mittal, A. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.05.010 · Cited by 174
Currow, D. C., Maddocks, M., Cella, D., & Muscaritoli, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113471 · Cited by 27
“Anamorelin is a novel, orally active, highly selective non-peptide ghrelin analogue that has been shown to simultaneously target multiple components of cancer cachexia, including appetite, body composition, adipose tissue metabolism, energy expenditure, and inflammation [36,37].”
BackgroundSelf-citation
Metadata
- Authors
- Currow, D. C., & Abernethy, A. P.
- Venue
- Future Oncology
- Publisher
- Informa UK Limited
- Published
- 2014-04
- Volume
- 10
- Issue
- 5
- Pages
- 789-802
- ISSN
- 1479-6694 (ISSN-L)
- 1744-8301
- OpenAlex
- W2138452959
- Cited by
- 42
- References
- 5
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.